Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-PsA 2 upadacitinib versus placebo in biologic-inadequate-response psoriatic arthritis
NL-OMON45660Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in psoriatic arthritis (PsA) (3 arms), sponsored by AbbVie Inc. Primary endpoint: ACR20 response. Started Jul 2018; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON45660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45660.